Related Experiment Video
Updated: Mar 28, 2026
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas
Tatiana N Buhtoiarova1, Carol A Brenner2, Meenakshi Singh3
1From the Department of Pathology.
Objectives:
Type II and other high-grade endometrial carcinomas may challenge conventional treatment due to recurrence and metastatic spread and therefore are a persistent clinical dilemma. Effective targeted therapy for these is a goal for clinicians and researchers alike.
Methods:
An extensive review of the literature has been performed for obtaining an in-depth understanding of the clinicopathological characteristics, etiologic factors, and molecular profile of these subsets of endometrial carcinoma. Progress made with current and emerging biomarkers for prognosis assessment and therapeutic targeting has been summarized.
Results:
There has been a significant increase in research on potential biomarkers of endometrial cancer, and beneficial targeted therapies have been identified.
Conclusions:
Clinical trials are leading the charge for substantial gains toward personalized treatment of aggressive endometrial carcinoma subtypes.
Insights
Targeted therapies and biomarkers show promise for treating aggressive endometrial cancer subtypes, addressing challenges of recurrence and metastasis. Clinical trials are advancing personalized treatment strategies for these difficult-to-treat cancers.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Translational Medicine
Background:
- High-grade endometrial carcinomas, including Type II, present significant clinical challenges due to high rates of recurrence and metastasis.
- Conventional treatments are often insufficient for these aggressive subtypes, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review clinicopathological characteristics, etiologic factors, and molecular profiles of aggressive endometrial carcinoma subsets.
- To summarize progress in prognostic and therapeutic biomarkers for endometrial cancer.
Main Methods:
- Extensive literature review focusing on clinicopathological data, etiology, and molecular aspects.
- Analysis of current and emerging biomarkers for prognosis and targeted therapy.
Main Results:
- Significant advancements in research identify potential biomarkers for endometrial cancer.
- Identification of beneficial targeted therapies for aggressive endometrial carcinoma subtypes.
Conclusions:
- Clinical trials are crucial for advancing personalized treatment for aggressive endometrial carcinoma.
- Emerging biomarkers and targeted therapies offer new hope for improved patient outcomes.
